The latest biotech news

News and Trends 8 Nov 2022

Lipum starts chronic inflammatory disease drug study

Lipum AB (publ) says its phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. A first dose group of eight healthy volunteers have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major […]

November 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Rallybio announces positive phase 1 results for drug treating PNH and gMG

Affibody’s licensee Rallybio Corporation has announced positive topline results from a phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Hormone discovery could predict long term health of men

Researchers have discovered the vital role of INSL3, a hormone that develops in men during puberty, which provides an early prediction of whether they could develop certain diseases in later life. Scientists from the University of Nottingham in the U.K. have discovered that the novel insulin-like peptide hormone, INSL3, is consistent over long periods of […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

More News! 7 Nov 2022

Sensorion granted rare pediatric disease designation by FDA for lead therapy gene

Sensorion has announced that the US Food and Drug Administration (FDA) has granted rare pediatric disease designation to its lead therapy gene candidate, OTOF-GT. The gene therapy is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion’s OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one […]

November 7, 2022 - 2 minutesmins - By Liza Laws

News and Trends 7 Nov 2022

TMRW Life Sciences FDA-approved tech will help more people start families

Fertility technology company, TMRW Life Sciences Inc., has received FDA clearance for its latest technology that will help more people build families. The CryoRobot Select marks the latest milestone in the company’s expansion of its technology-enabled portfolio. USA-based TMRW says advances like theirs in assisted reproductive technology are helping people start families when they otherwise […]

November 7, 2022 - 3 minutesmins - By Liza Laws

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 7 Nov 2022

Scancell in-licenses Vaccitech’s SNAPvax tech for cancer study

Scancell Holdings plc, a developer of immunotherapies, today (November 7) announced it has in-licensed the SNAPvax technology from Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines. The agreement will allow Scancell to formulate and manufacture Modi-2, with the aim of initiating a phase 1 clinical study […]

November 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Nov 2022

Proteins identified by FunSel and developed by Forcefield can preserve heart function

Forcefield Therapeutics, has presented positive preclinical data on three proteins identified by it FunSel platform that have the potential to preserve heart function following a heart attack. The company that works with therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction infarction. The paper, Novel Recombinant Cardioprotective Factors Against Myocardial […]

November 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Nov 2022

Ascentage Pharma gives positive news on chronic hepatitis B drug

Ascentage Pharma has released results from a phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB). The results were presented at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the world’s first clinical study reporting […]

November 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Nov 2022

First patient dose completed for bladder cancer diagnostic drug

Asieris Pharmaceuticals says it has completed the first patient dose in its phase III bridging trial for Hexvix, a drug used for the diagnosis of bladder cancer. Asieris Pharmaceuticals is a global biopharmaceutical company specializing in the discovery and development of drugs for the treatment of genitourinary tumors and other major diseases. The study is a […]

November 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Nov 2022

EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease

A phase 3 clinical trial, EMPA-KIDNEY, met its primary endpoint showing a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% versus placebo. The results were announced today during the American Society of […]

November 4, 2022 - 4 minutesmins - By Liza Laws

More News! 4 Nov 2022

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants was approved today (November 4). The European Commission has approved Beyfortus which is so far the first and only broadly protective option against the virus. Thomas Triomphe, executive vice president, […]

November 4, 2022 - 2 minutesmins - By Liza Laws

More News! 4 Nov 2022

Optibrium and Lhasa Limited study published on predictive modelling for enzymes

A peer reviewed study published in the Journal of Medicinal Chemistry has been published by Optibrium and Lhasa Limited that shows advance predictive modelling for drug-metabolizing enzymes. The companies are two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development. In the paper, ‘Predicting Regioselectivity of AO, CYP, […]

November 4, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Lipum starts chronic inflammatory disease drug study

Rallybio announces positive phase 1 results for drug treating PNH and gMG

Hormone discovery could predict long term health of men

Sensorion granted rare pediatric disease designation by FDA for lead therapy gene

TMRW Life Sciences FDA-approved tech will help more people start families

Scancell in-licenses Vaccitech’s SNAPvax tech for cancer study

Proteins identified by FunSel and developed by Forcefield can preserve heart function

Ascentage Pharma gives positive news on chronic hepatitis B drug

First patient dose completed for bladder cancer diagnostic drug

EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

Optibrium and Lhasa Limited study published on predictive modelling for enzymes

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!